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Abbreviations:  AMPK (AMP-activated protein kinase), ANOVA (analysis of variance), ATF4 37 
(activating transcription factor 4), BiP (binding immunoglobulin protein), BTZ (bortezomib), 38 
CASP (caspase), CHOP (C/EBP homologous protein), CI (combination index), ddCT (delta-39 
delta threshold cycle), DMEM (Dulbecco’s modified Eagle’s medium), DMSO (dimethyl 40 
sulfoxide), DTT (dithiothreitol), ELT3 (Eker rat leiomyoma-derived cells), ER (endoplasmic 41 
reticulum), ERO1L (endoplasmic reticulum oxidoreductase 1 alpha), ETO (etoposide), FBS 42 
(foetal bovine serum), GADD34 (growth arrest and DNA damage-inducible protein 34), 43 
GATOR (GTPase-activating protein activity toward RAGs), HSPA5 (heat shock protein family 44 
A [HSP70] member 5), IMPACT (impact RWD domain protein), IRE1α (inositol-requiring and 45 
ER-to-nucleus signaling protein 1α), K-RAS (KRAS Proto-Oncogene, GTPase), MEF (mouse 46 
embryonic fibroblast), mTORC1 (mammalian/mechanistic target of rapamycin complex 1), 47 
NFV (nelfinavir), PARP (poly[ADP-ribose] polymerase), PBS (phosphate buffered saline), 48 
PERK (PRKR-like endoplasmic reticulum kinase), PPI (protein phosphatase 1), PTEN 49 
(Phosphatase And Tensin Homolog), RAP (rapamycin), RIPA (radio immunoprecipitation 50 
assay), RPMI (Roswell Park Memorial Institute), SD (standard deviation), SESN2 (sestrin 2), 51 
TPG (thapsigargin), TRIB3 (tribbles homologue 3), TS (tuberous sclerosis), TSC (tuberous 52 
sclerosis complex), UPR (unfolded protein response), XBP1 (X-box binding protein 1). 53 
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Abstract 55 
Cancer cells typically lose homeostatic flexibility because of mutations and dysregulated 56 
signaling pathways involved in maintaining homeostasis. Tuberous Sclerosis Complex 1 57 
(TSC1) and TSC2 play a fundamental role in cell homeostasis, where signal transduction 58 
through TSC1/TSC2 is often compromised in cancer, leading to aberrant activation of 59 
mechanistic target of rapamycin complex 1 (mTORC1). mTORC1 hyperactivation increases 60 
the basal level of endoplasmic reticulum (ER) stress via an accumulation of unfolded protein, 61 
due to heightened de novo protein translation and repression of autophagy. We exploit this 62 
intrinsic vulnerability of tumor cells lacking TSC2, by treating with nelvinavir to further 63 
enhance ER stress while inhibiting the proteasome with bortezomib to prevent effective 64 
protein removal. We show that TSC2-deficient cells are highly dependent on the 65 
proteosomal degradation pathway for survival. Combined treatment with nelfinavir and 66 
bortezomib at clinically relevant drug concentrations show synergy in selectively killing 67 
TSC2-deficient cells with limited toxicity in control cells. This drug combination inhibited 68 
tumor formation in xenograft mouse models and patient-derived cell models of TSC and 69 
caused tumor spheroid death in 3D culture. Importantly, 3D culture assays differentiated 70 
between the cytostatic effects of the mTORC1 inhibitor, rapamycin and the cytotoxic effects 71 
of the nelfinavir/bortezomib combination. Through RNA sequencing, we determined that 72 
nelfinavir and bortezomib tip the balance of ER protein homeostasis of the already ER-73 
stressed TSC2-deficient cells in favour of cell death. These findings have clinical relevance in 74 
stratified medicine to treat tumors that have compromised signaling through TSC and are 75 
inflexible in their capacity to restore ER homeostasis. 76 
Keywords: 77 
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 79 
 80 
1. Introduction 81 
Cancer cells often exhibit enhanced endoplasmic reticulum (ER) stress, due to a combination 82 
of inappropriately activated protein synthesis, high mutational load, oxidative stress and 83 
relative nutrient depletion that leads to the accumulation of misfolded protein [1]. The 84 
unfolded protein response (UPR) pathway restores ER homeostasis by three main 85 
mechanisms; by slowing the rates of global protein translation, by targeting unfolded 86 
protein to proteolytic degradation pathways (such as through autophagy and the 87 
proteasome), and through enhancement of protein folding orchestrated by molecular 88 
protein chaperones within the ER. If the UPR fails to restore the ER protein folding 89 
environment in a timely manner, cell death will ensue. 90 
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Mechanistic target of rapamycin (mTOR) (also referred to as mammalian target of 91 
rapamycin) orchestrates cell growth control by functioning as a key regulator of protein 92 
translation. Hyperactivation of mTOR complex 1 (mTORC1) is known to elevate the basal 93 
levels of ER stress through inappropriately high levels of protein synthesis and an 94 
accumulation of unfolded protein [2]. Aberrant signal transduction through mTORC1 can 95 
also potently repress autophagy (reviewed in [3]). When autophagy is compromised, the 96 
proteasome becomes the primary proteolytic pathway to clear unfolded protein aggregates 97 
from the cell, thereby restoring ER homeostasis and preventing cell death [4]. 98 
Inactivating mutations in either Tuberous Sclerosis Complex 1 (TSC1) or TSC2 give rise to 99 
Tuberous Sclerosis (TS), a genetic disorder where patients are predisposed to mTORC1-100 
dependent tumor growth in various organs including the brain, kidney, eyes, lung, heart, 101 
and skin (for review see [5]). Functional loss of TSC2 and resulting activation of mTORC1 was 102 
shown to upregulate the proteasome [6]. We hypothesise that mTORC1-driven cancers have 103 
an increased dependency on the proteasome for survival in response to ER stress. 104 
Therefore, a feasible therapeutic strategy might be to inhibit the proteasome with the aim 105 
to increase ER stress beyond a tolerated survival threshold. In support of this concept, 106 
selective cytotoxicity of proteasome inhibitors has been shown in cancer cell models with 107 
heightened mTORC1 signaling [7,8]. However, the proteasome inhibitor, bortezomib, had 108 
little efficacy as a single agent in preventing renal cystadenoma development in vivo in a 109 
Tsc2+/- mouse model [9]. This study suggested that targeting the proteasome alone is 110 
unlikely to cause cytotoxicity in mTORC1-active tumors. We therefore examined the effects 111 
of targeting the proteasome with bortezomib in combination with nelfinavir. Nelfinavir was 112 
originally used as a HIV protease inhibitor but has shown activity against a broad range of 113 
cancer models. One of its proposed mechanisms of anti-cancer action is via induction of ER 114 
stress [10]. Bortezomib has enhanced activity against advanced haematological 115 
malignancies such as multiple myeloma, recurrent multiple myeloma and mantle cell 116 
lymphoma when combined with nelfinavir and this combination is well tolerated in patients 117 
[11]. Combined nelfinavir and bortezomib therapy is cytotoxic to breast cancer, acute 118 
myeloid leukaemia, non-small cell lung cancer and myeloma cancer models [12,13,14], 119 
prompting several clinical trials (ClinicalTrials.gov: NCT01164709, NCT02188537, 120 
NCT01555281). 121 
In an effort to stratify therapy, we wanted to determine whether specific inactivation of 122 
TSC2, a key regulator of mTORC1, would sensitise cell and tumor models to combined 123 
nelfinavir and bortezomib treatment. Previously we showed that combined treatment with 124 
nelfinavir and the autophagy inhibitor, chloroquine, was sufficient to kill TSC2-deficient cell 125 
lines or cancer cells with a high level of mTORC1 signal transduction and ER stress burden 126 
[15]. In this study, using both in vitro and in vivo mTORC1-hyperactive tumor models, we 127 
reveal that mTORC1-hyperactive cell lines and tumors are sensitive to combination 128 
nelfinavir and bortezomib induced cytotoxicity mediated through ER stress, while normal 129 
cells are able to tolerate this drug combination through intact compensatory mechanisms.  130 
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2. Results 131 
2.1. ER stress is elevated upon combined treatment with nelfinavir and bortezomib in Tsc2-132 
/- MEFs. 133 
To assess ER stress induction after combined nelfinavir and bortezomib treatment, we 134 
analysed downstream ER stress markers by western blotting. As a control we employed 135 
MG132 to inhibit the proteasome. Nelfinavir and bortezomib individually enhanced the level 136 
of ER stress in Tsc2-/- MEFs, as shown by increases in ATF4, CHOP and GADD34 protein 137 
levels, while induction of ATF4, CHOP and GADD34 in Tsc2+/+ MEFs was less evident (Figure 138 
1A). Combined nelfinavir and bortezomib treatment further elevated the protein levels of 139 
ATF4, CHOP and GADD34 compared to single drug treatment, particularly in Tsc2-/- MEFs.  140 
We next analysed Xbp1 mRNA splicing, which is a functional readout of ER stress and IRE1α 141 
activation. Tharpsigargin was employed as a control drug to induce ER stress. We observed 142 
more Xbp1 mRNA splicing upon nelfinavir treatment in both the Tsc2+/+ and Tsc2-/- MEFs. 143 
Bortezomib treatment did not result in Xbp1 mRNA splicing as a single agent and did not 144 
further enhance the splicing of Xbp1 mRNA when combined with nelfinavir (Figure 1B). To 145 
confirm this differential ER stress induction between cells with and without Tsc2, we 146 
examined the mRNA levels of Chop and Bip (Figure 1C). In untreated cells, both the Chop 147 
and Bip mRNA in Tsc2-/- MEFs were 5-fold and 2-fold higher, respectively, when compared 148 
to Tsc2+/+ MEFs, indicating that ER stress is basally elevated in Tsc2-/- MEFs. The Tsc2-/- 149 
MEFs were particularly sensitive to nelfinavir treatment (either as a single agent or in 150 
combination with bortzomib), resulting in a 2.5 – 3.3-fold higher level of Chop expression 151 
and a 1.8 – 2.2-fold higher level of Bip expression when compared to the Tsc2+/+ cells. 152 
Bortezomib also induced a 3-fold increase in Chop mRNA and a 2.4-fold increase in Bip 153 
mRNA in the Tsc2-/- cells compared to the control cells. These data demonstrate that both 154 
nelfinavir and bortezomib treatment induce a higher ER stress burden in cells lacking Tsc2. 155 
To examine whether drug treatment was inducing CHOP via the PERK pathway, we 156 
employed a PERK inhibitor, GSK2606414 (Figure 1D). CHOP expression induced by nelfinavir 157 
and bortezomib was markedly repressed with GSK2606414, revealing that these drugs are 158 
inducing an ER stress response through PERK. 159 
Given that bortezomib promotes ER stress via proteasomal inhibition and that nelfinavir has 160 
also been reported to inhibit the proteasome [16], we examined proteasome activity 161 
through either detection of polyubiquitinated protein (Figure 1A), or levels of chymotrypsin-162 
like activity (Figure 1E) after drug treatment. As expected, treatment with bortezomib alone, 163 
or in combination, greatly enhanced the levels of polyubiquitinated protein and effectively 164 
reduced chymotrypsin-like activity, indicating robust proteasome inhibition. At 20 µM, 165 
nelfinavir did not show proteasome inhibition in either assay.  166 
Elevation of protein synthesis by mTORC1 hyperactivation likely drives ER stress in Tsc2-167 
deficient cells, but has not been examined to date. We analysed de novo protein synthesis 168 
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using pulse-chase [35S]-methionine labelling experiments of Tsc2-/- and wild-type control 169 
cells in the presence or absence of nelfinavir and bortezomib (Figure 1F). We observed that 170 
the Tsc2-/- cells had almost 4-fold elevation of protein synthesis compared to wild-type, 171 
showing that basally ER stressed Tsc2-/- cells maintain a high level of protein synthesis. After 172 
6 h of nelfinavir and bortezomib dual treatment, protein translation was markedly reduced. 173 
2.2. Proteasome inhibition induced death of Tsc2 deficient cells which is enhanced by 174 
nelfinavir. 175 
We speculated that combined nelfinavir and bortezomib treatment might selectively induce 176 
cell death in Tsc2-/- MEFs compared to Tsc2+/+ MEFs. We quantified cell death by flow 177 
cytometry with DRAQ7 labelling (Figures 2A and 2B). DRAQ7 is a membrane impermeable 178 
far-red fluorescent DNA-binding dye that measures cell death via increased membrane 179 
permeability. Both MG132 and bortezomib as single agents caused selective cell death in 180 
the Tsc2-/- MEFs but not in Tsc2+/+ MEFs, revealing that cells devoid of Tsc2 are dependent 181 
on the proteasome for their survival. Combined treatment of nelfinavir with bortezomib 182 
enhanced cell death in the Tsc2-/- MEFs (83.2% ± 9.2 cell death), with minimal toxicity 183 
observed in the Tsc2+/+ MEFs (17.5% ± 7.7). The low level of cell death in the Tsc2+/+ MEFs 184 
is not significantly different to the DMSO vehicle control. A similar pattern was observed for 185 
the nelfinavir/MG132 combination. To validate these findings, we utilised Tsc2-deficient and 186 
re-expressing ELT3 rat smooth muscle cells [17]. These results mirrored that seen in the 187 
Tsc2-/- MEFs (Supplementary Figure 1A and 1B). 188 
To further examine cell death in Tsc2-/- MEFs we quantified DNA fragmentation after 189 
treatment (Figure 2C). We observed significant induction of DNA fragmentation after 190 
bortezomib treatment, which was further enhanced when combined with nelfinavir. No 191 
DNA fragmentation was evident with nelfinavir treatment alone. We next analysed several 192 
apoptosis markers by western blot (Supplementary Figure 1C). We observed cleavage of 193 
caspase8, caspase 3 and PARP in Tsc2-/- MEFs upon treatment with bortezomib alone or co-194 
treatment with nelfinavir and proteasome inhibitors, whilst no marked cleavage was 195 
observed in wild-type cells. We could partially but significantly rescue Tsc2-/- MEFs from 196 
nelfinavir/bortezomib-induced cell death by inhibiting apoptosis with the pan caspase 197 
inhibitor, Z-VAD-FMK, suggesting cell death is partly mediated through caspase activation 198 
(Figure 2D).  199 
To determine whether other sporadic cancer cell lines were also sensitive to combined 200 
nelfinavir and bortezomib treatment, we examined human NCI-H460 lung cancer and 201 
HCT116 colon cancer cell lines, which both have elevated levels of mTORC1 signaling. Both 202 
cell lines showed sensitivity to the treatment (Figures 3A and 3B). Combined treatment 203 
caused cell death at levels of 58.1% ± 18.5 in NCI-H460 cells and 55.1% ± 5.8 in HCT116 cells, 204 
significantly higher than with either agent alone. Both cell lines showed a higher level of 205 
caspase 8, caspase 3, and PARP cleavage following dual treatment when compared to single 206 
drug treatments (Figure 3C). Elevated levels of CHOP and GADD34 were observed in 207 
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nelfinavir and bortezomib treated cells, suggesting that cell death was likely mediated 208 
through the ER stress pathway. 209 
2.3. Synergy of nelfinavir and bortezomib in inducing cell death in Tsc2-/- MEFs 210 
We next assessed evidence for synergy between nelfinavir and bortezomib in inducing cell 211 
death. Tsc2+/+ and Tsc2-/- MEFs were treated with nelfinavir and bortezomib at a range of 212 
concentrations, both separately and in combination. Cells were then analysed by flow 213 
cytometry using DRAQ7 labelling (Figures 4A-D) revealing that nelfinavir has little cytotoxic 214 
effect as a single agent, especially at low doses (Figure 4A), whilst bortezomib potently 215 
induces cell death, more so in Tsc2-/- than Tsc2+/+ cells (Figure 4B). Whilst Tsc2+/+ MEFs 216 
can tolerate high concentrations of nelfinivir and bortezomib in combination (Figure 4C), 217 
Tsc2-/- MEFs are acutely sensitive to lower drug concentrations (Figure 4D). CompuSyn 218 
software was used to calculate combination index (CI) values based on mean cell death, 219 
which are shown as Chou-Talalay plots for Tsc2+/+ (Figure 4E) and Tsc2-/- (Figure 4F) MEFs. 220 
Values below CI = 1 indicate synergy between nelfinavir with bortezomib. Figure 4F shows 221 
that nelfinavir and bortezomib act synergistically to induce cell death in Tsc2-/- MEFs at all 222 
concentrations used in this experiment. 223 
2.4. Combined nelfinavir and bortezomib inhibit tumor spheroid formation and outgrowth 224 
of Tsc2-/- cells 225 
Based on the concentrations of nelfinavir and bortezomib that demonstrated synergy in 226 
Tsc2-/- MEFs, we utilised 20 nM bortezomib with 20 µM nelfinavir in tumor formation 227 
assays. Nelfinavir alone did not impact colony formation and growth, but bortezomib 228 
treatment impaired growth by 36 ± 12% (Figure 5A). When bortezomib was combined with 229 
nelfinavir, tumor growth was completely inhibited. To investigate whether nelfinavir and 230 
bortezomib could kill already established tumors, Tsc2-/- MEFs were cultured as spheroids 231 
using 3D cell culture before being treated over 96 h. Nelfinavir and bortezomib as single 232 
drug treatments and also in combination were compared to the mTORC1 inhibitor, 233 
rapamycin. Due to the prolonged treatment time compared to the 2D experiments, we 234 
utilised lower concentrations of nelfinavir (10 μM) and bortezomib (10 nM) in this 235 
experiment. Cell death was measured by DRAQ7 staining intensity (Figure 5B) and compared 236 
to spheroid size (Figure 5C). Combined nelfinavir and bortezomib treatment caused a 237 
significant increase in DRAQ7 staining compared to both the single drug treatments and also 238 
when compared to rapamycin. However, rapamycin visibly shrank the overall size of the 239 
spheroid whereas treatments with either nelfinavir or bortezomib did not. To further 240 
determine viability, the treated spheroids shown in Figure 5B were plated into 2D cell 241 
culture systems and allowed to regrow without the presence of drug. Spheroid outgrowth 242 
was then measured over 72 h (Figure 5D, graphed in 5E). Spheroids treated with rapamycin, 243 
although shrunken, still contained viable cells that could rapidly grow out into culture. 244 
Spheroids treated with either nelfinavir or bortezomib also grew back, while there was no 245 
evidence of outgrowth in the combined treatment with nelfinavir and bortezomib. The lack 246 
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of cell recovery and the high level of DRAQ7 staining indicate that combined treatment with 247 
nelfinavir and bortezomib effectively prevents re-growth of spheroids through induction of 248 
cell death, whereas rapamycin shrank spheroids which then regrew when treatment was 249 
withdrawn, as previously reported in clinical studies with rapalogues [18,19]. The effect of 250 
nelfinavir and bortezomib in Tsc2-/- MEFs was validated in ELT3-V3 cells that showed a 251 
similar response (Supplementary Figure S2A-C). To further investigate how drug treatments 252 
affected tumor size and integrity, phalloidin (green) was used to stain the actin 253 
cytoskeleton, and DRAQ7 (far red) to counterstain nuclei, following drug treatment of Tsc2-254 
/- MEFs. Figure 5F shows that rapamycin-treated spheroids retain a similar degree of actin 255 
fluorescence as DMSO-treated controls, whereas nelfinavir and bortezomib-treated 256 
spheroids exhibit comparatively less actin and nuclear staining. The weak nuclear staining 257 
and the collapse of the nuclear envelope is indicative of DNA fragmentation and suggests 258 
that nelfinavir-bortezomib is killing cells in the spheroid rather than causing senescence. 259 
This data supports our findings showing that rapamycin can shrink tumors, but without 260 
cytotoxic effects, while nelfinavir-bortezomib treatment is effective at causing cell death.  261 
2.5. Nelfinavir and bortezomib treatment downregulates pro-survival and upregulates 262 
pro-apoptosis genes, likely mediated through ER stress 263 
To gain a better understanding of the early changes that nelfinavir and bortezomib cause to 264 
gene expression within cells, RNA sequencing was performed in Tsc2+/+ and Tsc2-/- MEFs 265 
after 6 h of combined treatment or DMSO vehicle control. Figure 6A shows a panel of genes 266 
associated with ER stress, a selection of which is highlighted graphically in Figure 6B (raw 267 
data in Supplementary Table 1). Tsc2-/- MEFs expressed higher basal levels of all the ER 268 
stress genes shown in the panel (Figure 6A, Supplementary Figure S3A and Supplementary 269 
Table 2). Following nelfinavir and bortezomib treatment, this expression was further 270 
increased (Supplementary Figure S3B and Supplementary Table 3), with expression in Tsc2-271 
/- cells mostly significantly higher than that of the Tsc2+/+ MEFs (Figure 6B). Figure 6C 272 
describes the changes of a panel of pro-survival and pro-death genes in Tsc2+/+ versus Tsc2-273 
/- dual-treated MEFs (genes selected based on AmiGO “cell death”). Figure 6C shows 274 
expression of pro-survival genes to be decreased, and pro-death genes to be increased in 275 
drug treated Tsc2-/- cells compared to treated Tsc2+/+ MEFs. The overall RNA sequencing 276 
data is shown visually in a volcano plot (Figure 6D and Supplementary Table 4), with the 277 
genes in Figure 6C highlighted.  To validate that the Tsc2+/+ MEFs could efficiently restore 278 
ER homeostasis, while the Tsc2-/- MEFs could not, we carried out a time course of 279 
nelfinavir-bortezomib treatment (Figure 6E). We observed a strong initial increase in ATF4 280 
and CHOP protein in both cell lines at 6 h of treatment, which was downregulated by 16 h to 281 
a level that was not significantly different to untreated. However, after 24 h of treatment, 282 
the protein expression of ATF4 and CHOP was enhanced in the Tsc2-/- MEFs, suggesting an 283 
inability to efficiently restore ER homeostasis. In contrast, the protein levels of ATF4 and 284 
CHOP remained low in the Tsc2+/+ MEFs after 24 h of treatment. 285 
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2.6. Nelfinavir and bortezomib treatment reduced tumor volume in ELT-V3 mouse 286 
xenografts, correlating with increased CHOP expression in tumor tissue 287 
To determine the anti-tumor efficacy of nelfinavir and bortezomib in vivo, mice bearing 288 
Tsc2-null ELT3 xenograft tumors were treated with the drugs as single agents or in 289 
combination. Thirty-five days after commencement of treatment, combined nelfinavir and 290 
bortezomib decreased tumor growth by approximately 70% which was a significant 291 
decrease compared with vehicle-treated mice (Figure 7A). The single agent treatments 292 
slowed tumor growth but not significantly. While combined treatment of nelfinavir and 293 
bortezomib is well tolerated in patients [11], combined treatment was not well tolerated in 294 
mice. In the combination group, 11/14 mice died or were euthanized due to excessive 295 
toxicity compared with 2/14 in the vehicle treated group, 5/14 in the nelfinavir alone group 296 
and 5/14 in the bortezomib alone group. Immunohistochemical analysis of xenograft tumor 297 
tissue sections revealed a modest increase in CHOP positive cells after nelfinavir and 298 
bortezomib combined treatment (Figure 7B). The heterogeneity of CHOP staining likely 299 
reflects cycles of ER stress induction and recovery in these cells. By western blot analysis, a 300 
higher level of ATF4 protein and PARP cleavage was observed in tumors from mice that 301 
were treated with both nelfinavir and bortezomib (Figure 7C), which indicates an elevated 302 
level of ER stress and cell death upon combined drug treatment.  303 
3. Discussion 304 
In this study, using clinically relevant drugs that could be repositioned to treat tumors 305 
displaying high ER stress profiles, we reveal that mTORC1-overactive cells are sensitive to 306 
combined nelfinavir and bortezomib treatment. We show that nelfinavir and bortezomib act 307 
to amplify ER stress levels, and combine synergistically to promotecell death. Whilst wild-308 
type cells tolerate this drug combination with minimal cell death, cytotoxicity in Tsc2-309 
deficient cells is evident even at low drug concentrations and is likely attributable to their 310 
inability to manage the ER stress burden. Indeed, we see that ER stress is not fully restored 311 
in the Tsc2-deficient cells after 24 h of combined drug treatment, as observed by a 312 
reoccurrence of ATF4 and CHOP protein expression (Figure 6E). It was previously reported 313 
that Tsc2-deficient cells have a truncated ER stress response [20], which fits with our 314 
observation that cells lacking functional Tsc2 are compromised in their ability to reduce 315 
their ER stress burden and restore ER homeostasis. Tsc2 functions as an important 316 
component of the survival arm during ER stress as it is positioned downstream of several ER 317 
stress-mediated survival pathways. One pathway involves GADD34, which associates with 318 
Tsc2 to recruit protein phosphatase 1 (PP1) to dephosphorylate and activate Tsc2, thus 319 
repressing mTORC1 signal transduction. We observed high protein expression levels of 320 
GADD34 after ER stress induction in all our cell lines, more so in Tsc2-/- MEFs. 321 
Normally, protein synthesis is down-regulated upon ER stress as an efficient strategy to 322 
prevent further build-up of unfolded protein within the ER. We observed that Tsc2-deficient 323 
cells have elevated protein synthesis despite the higher background levels of ER stress, with 324 
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a 3 to 4-fold increase in protein synthesis in Tsc2-/- MEFs compared to wild-type (Figure 1F). 325 
The elevated levels of protein synthesis would likely enhance ER stress within the Tsc2-326 
deficient cells. As well as promoting translation, mTORC1 hyperactivation increases the 327 
activity of the proteasome while reducing autophagy [6]. Downregulation of autophagy 328 
means the proteasome becomes the principal mechanism to reduce ER stress via protein 329 
degradation in mTORC1-driven cells. However, the proteasome inhibitor, bortezomib, had a 330 
lack of in vivo activity against renal tumors in Tsc2+/− mice as a single agent [9], perhaps 331 
reflecting a failure to induce a sufficient level of ER stress. This problem could potentially be 332 
overcome by using a combination of two ER stress inducing agents, such as nelfinavir and 333 
bortezomib. 334 
Bortezomib (Velcade, Janssen-Cilag) was the first FDA-approved proteasome inhibitor found 335 
to have clinical promise for treating cancer. Bortezomib was originally approved for the 336 
treatment of advanced multiple myeloma and more recently for mantle cell lymphoma. 337 
Next generation proteasome inhibitors (marizomib and carfilzomib) are currently being 338 
tested in clinical trials. Bortezomib’s action is to specifically bind to the catalytic site of the 339 
26S proteasome to inhibit enzyme activity. As a consequence of inhibiting the ubiquitin–340 
proteasome system, bortezomib markedly changes the survival status of cancer cells. The 341 
synergy observed between nelfinavir and bortezomib is unlikely due to ER stress alone, but 342 
probably involves other processes impacted by treatment. Additional processes affected 343 
upon proteasome inhibition include cell cycle control, apoptosis, angiogenesis, 344 
transcriptional regulation and DNA-damage response (see review [21]). Although the 345 
nelfinavir and bortezomib combination showed considerable toxicity in mice in our study, a 346 
recent phase I clinical trial (clinicaltrials.gov: NCT01164709) in bortezomib-refractory 347 
multiple myeloma combining bortezomib with nelfinavir was well tolerated, safe and 348 
showed promising activity [11]. Supporting this, treatment of patients with a recommended 349 
dose for a phase II trial of advanced haematological malignancies showed that 9 relapse 350 
patients whose malignancies were resistant to bortezomib had either a partial response or 351 
clinical benefit when bortezomib was combined with nelfinavir, with no apparent increase in 352 
toxicity [11]. 353 
Our work demonstrates for the first time that functional loss of TSC2 and subsequent 354 
mTORC1 hyperactivation sensitises cells to combined proteasomal inhibition and ER stress 355 
induction. Our findings have clinical relevance in stratified medicine, where cancers with 356 
compromised signal transduction through TSC1/2-mTORC1 (via upstream pathways e.g. 357 
oncogenic K-RAS or loss of PTEN) may be sensitive to nelfinavir and bortezomib. Our data 358 
implies that a high ER stress burden and hyperactive mTORC1 signaling could function as 359 
predictive biomarkers of drug efficacy when considering combined nelfinavir and 360 
bortezomib treatment. 361 
 362 
 363 
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 364 
4. Materials and Methods 365 
4.1. Cell culture and reagents 366 
Tsc2+/+ p53-/- and Tsc2-/- p53-/- mouse embryonic fibroblasts (MEFs) were a kind gift from 367 
David Kwiatkowski (Harvard University, Boston, USA) in 2004 and have been previously 368 
characterised [22]. Eker rat leiomyoma-derived Tsc2-deficient ELT3-V3 cells and matching 369 
control TSC2-expressing ELT3-T3 cells generated in Astrinidis et al, 2002 [23], were kindly 370 
provided in 2006 by Cheryl Walker (M.D. Anderson Cancer Center, Houston, USA). Human 371 
lung carcinoma (NCI-H460) cells were purchased from ATCC in 2012 while HCT116 cells were 372 
provided in 2015 by Nick Leslie (Heriot Watt University, Edinburgh). All cell lines were 373 
mycoplasma free and regularly tested for mycoplasma infection using the Venor GeM 374 
Classic PCR kit from CamBio. All cell lines were cultured in Dulbecco’s Modified Eagle’s 375 
Medium (DMEM, Lonza, Basel, Switzerland, BE12-604F), supplemented with 10 % (v/v) 376 
foetal bovine serum (FBS, 10270106, Thermo Fisher Scientific), 100 U/ml penicillin and 100 377 
µg/ml streptomycin (P4333, Sigma-Aldrich, Dorset, UK) in a humidified incubator at 37 °C, 5 378 
% (v/v) CO2. Nelfinavir mesylate hydrate (PZ0013), thapsigargin (T9033), MG132 (C2211) 379 
and etoposide (E1383) were purchased from Sigma, while bortezomib (CAS 179324-69-7), 380 
rapamycin (CAS 53123-88-9), Z-VAD-FMK (CAS 161401-82-7), and GSK2606414 were 381 
purchased from Merck Millipore (Hertfordshire, UK). 382 
4.2. mRNA extraction, reverse transcription, XBP1 splicing, Chop and Bip qPCR 383 
Samples were collected and analysed as previously described [15]. Bip was analysed using 384 
Quantitect primers (QT00172361, Qiagen). 385 
4.3. Western Blotting 386 
Both live and dead cells were collected and lysed in radio immunoprecipitation assay (RIPA) 387 
buffer (R0278) supplemented with Complete Mini protease inhibitor cocktail 388 
(11836170001), PhosSTOP phosphatase inhibitor cocktail (04906837001) and 1 mM 389 
dithiothreitol (DTT, D0632) (all purchased from Sigma). Following sonication, equal amounts 390 
of protein were loaded and western blotting was performed as previously described [24]. 391 
Protein from xenograft tumors were extracted by AllPrep DNA/RNA/Protein Mini Kit using 392 
the manufacturers protocol (Qiagen). Antibodies towards C/EBP homologous protein 393 
(CHOP, #2895), inositol-requiring and ER-to-nucleus signaling protein 1α (IRE1α, #3294S), 394 
ATF4 (#11815), caspase-3 (#9662), caspase-8 (mouse specific #4927, human specific  #9746), 395 
PARP (#9542), TSC2 (#3990) and β-actin (#4967) were purchased from Cell Signaling 396 
Technology (Danvers, USA). Growth arrest and DNA damage-inducible protein 34 (GADD34, 397 
also known as Protein phosphatase 1 regulatory subunit 15A [PPP1R15A], 10449-1-AP) 398 
antibody was purchased from Proteintech (Manchester, UK). Ubiquitin antibody was from 399 
BioMol (PW8810). Densitometry was carried out using ImageJ (version 1.51j8). 400 
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 401 
4.4. Late cell death assay and determination of drug synergy 402 
Cell death was quantified as previously described [15]. To determine synergy, cells were 403 
treated with a range of drug concentrations and the affected fraction was used to 404 
determine combination index (CI) values using CompuSyn software (ComboSyn, Inc.) using a 405 
non-constant ratio approach. 406 
4.5. DNA fragmentation ELISA 407 
DNA fragmentation was measured with the Cell Death Detection ELISA kit (Roche) according 408 
to the manufacturer’s protocol. This is a one-step colorimetric sandwich ELISA that 409 
quantifies DNA fragments. Tsc2+/+ and Tsc2-/- MEFs were plated in 96-well plates and 410 
incubated overnight. Drugs were added to the cells and incubated for 24 h and DNA 411 
fragmentation assayed. The relative quantity of immobilized antibody histone complex was 412 
determined photometrically (at 405 nm) using 2,2,0-azino-bis-3-ethylbenzothiazoline-6-413 
sulfonic acid as a peroxidase substrate. 414 
4.6 Proteasome Activity Analysis 415 
Proteasomes were extracted from live cells 2 h post-treatment and their chymotrypsin-like 416 
proteasome activity determined according to a previously described protocol [25].  417 
4.7 Soft Agar Assay, spheroids and outgrowth 418 
Soft agar assays, spheroid formation and outgrowth analysis was performed as previously 419 
described [26]. For phalloidin staining, spheroids were grown over 96 h and drug treated for 420 
72 h, before fixing in 4% paraformaldehyde for 30 min. Spheroids were permeabilized using 421 
0.1% Triton-X100 for 45 min before staining with ActinGreen 488 Ready Probes Reagent 422 
(R37110, Thermo Fisher) as per manufacturers protocol. Finally, spheroids were stained 423 
with 3 μM DRAQ7 (DR71000, Biostatus) before transfer to a glass-bottomed plate and 424 
imaged using a Zeiss LSM 880 confocal microscope with Zen software. Analysis was 425 
performed using ImageJ v1.50i. 426 
4.8 RNA-Seq sample preparation, sequencing and analysis 427 
Total RNA quality and quantity was assessed using Agilent 2100 Bioanalyser and a RNA Nano 428 
6000 kit (Agilent Technologies). 100-900 ng of total RNA with a RIN value >8 was depleted of 429 
ribosomal RNA and the sequencing libraries were prepared using the Illumina® TruSeq® 430 
Stranded total RNA with Ribo-Zero Gold™ kit (Illumina Inc.). The steps included rRNA 431 
depletion and cleanup, RNA fragmentation, 1st strand cDNA synthesis, 2nd strand cDNA 432 
synthesis, adenylation of 3’ ends, adapter ligation, PCR amplification (12-cycles) and 433 
validation. The manufacturer’s instructions were followed except for the cleanup after the 434 
ribozero depletion step where Ampure®XP beads (Beckman Coulter) and 80% Ethanol were 435 
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used. The libraries were validated using the Agilent 2100 Bioanalyser and a high-sensitivity 436 
kit (Agilent Technologies) to ascertain the insert size, and the Qubit® (Life Technologies) was 437 
used for quantitation. Following validation, the libraries were normalized to 4 nM, pooled 438 
together and clustered on the cBot™ 2 following the manufacturer’s recommendations. The 439 
pool was then sequenced using a 75-base paired-end (2x75bp PE) dual index read format on 440 
the Illumina® HiSeq2500 in high-output mode according to the manufacturer’s instructions. 441 
Quality control checks of the resultant reads were performed using FastQC before mapping 442 
to the UCSC mouse mm10 reference genome using Tophat and Bowtie. Differentially 443 
expressed transcripts were identified using a DeSeq2 analysis [27] on normalised count data 444 
with the design formula setup to analyse all pairwise comparisons in the dataset using 445 
contrasts.  The resultant p-values were corrected for multiple testing and false discovery 446 
issues using the FDR method. Genes involved in cell survival were selected based on 447 
GO:0008219 (cell death) from the complete list on AmiGo 2 448 
(http://amigo.geneontology.org/amigo/landing). 449 
4.9 Protein translation assay 450 
This was performed as in [28], using EasyTag™ EXPRESS-[35S] Protein Labeling Mix 451 
(NEG772007MC, Perkin Elmer).  452 
 453 
4.10 ELT-3 mouse xenograft 454 
All animal experimental procedures were approved by the Institutional Animal Care and Use 455 
Committee of CrownBIO prior to conduct. During the study, the care and use of animals was 456 
conducted in accordance with the regulations of the Association for Assessment and 457 
Accreditation of Laboratory Animal Cate (AAALAC). A mouse xenograft model was 458 
established using ELT3-V3 cells inoculated into 9-10 week old female NOD/SCID mice (HFK 459 
Bio-Technology Co. Ltd. (Beijing, China)). Sample size was based upon using a two tailed t-460 
test, assuming unequal variance and large effect size of 0.8 with 60 % power at the 10 % 461 
significance level. Exponentially growing ELT3-V3 cells were used for tumor inoculation. One 462 
week prior to cell inoculation, all the mice were implanted with 17-β estradiol pellets (2.5 463 
mg, 90-day release, Innovative Research of America). Mice were inoculated subcutaneously 464 
at the right flank with ELT3-V3 cells (5×106) in 0.2 ml of PBS. Tumor volumes were measured 465 
in two dimensions using a calliper, and the volume was expressed in mm3 using the formula: 466 
V = 0.5 a × b2 where a and b are the long and short diameters of the tumor, respectively. 467 
Grouping and treatments began when the mean tumor size reached 186 mm3. Fourteen 468 
mice were assigned per treatment group using a randomized block design, based on their 469 
tumor volumes to receive one of the following treatments: 1) vehicle (4 % (v/v) DMSO, 5 % 470 
(v/v) PEG, 5 % (v/v) TWEEN 80 in saline); 2) nelfinavir, 50 mg/kg dissolved in vehicle; 3) 471 
bortezomib, 0.5 mg/kg dissolved in 0.04 % (v/v) mannitol solution; 4) nelfinavir, 50 mg/kg 472 
and bortezomib,0.5 mg/kg. Treatments were administered intraperitoneally on days 1, 3, 5, 473 
8, 10, 12, 15 and 17. Dosages were reduced to 30 mg/kg nelfinavir and 0.3 mg/kg 474 
bortezomib on day 8 due to toxicity. Tumor volumes were measured three times per week. 475 
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Investigators were not blinded to the group allocation. Due to lower numbers of mice than 476 
anticipated at Day 17, groups were compared non-parametrically using the Kruskal-Wallis 477 
test and pairwise comparisons.  478 
4.11  Immunohistochemistry 479 
Tumors were snap frozen in optimal cutting temperature compound and cryostat sectioned 480 
at 10 µm thickness. Sections were warmed to room temperature for 30 min, fixed in ice cold 481 
acetone for 5 min and air-dried for 30 min. Following blocking in 5% (v/v) normal goat 482 
serum (NGS) in Tris Buffered Saline (pH 7.6) 0.1 % (v/v) Tween-20, sections were incubated 483 
over-night at 4oC with 1/1000 rabbit monoclonal antibody against CHOP(Abcam, ab179823), 484 
blocked with Envision peroxidase block and incubated for 30 min in Envision rabbit polymer, 485 
before detection with DAB chromogen (all DAKO). Slides were counterstained with 486 
haematoxylin, dehydrated through an ethanol series and xylene, before mounting in DPX 487 
medium (Fisher Scientific). 5 fields from each tumor were scored for percentage of cells 488 
staining positively for CHOP (ImageJ, v1.51j8). 489 
4.12 Statistical analysis 490 
At least three independent, biological repeats were performed for each experiment. Exact 491 
sample size is indicated in each figure legend. Results are expressed as mean ± standard 492 
deviation (SD), unless otherwise specified in the figure legend. Data analysis was carried out 493 
using a one-way ANOVA followed by LSD post-hoc test, or an independent samples Kruskal-494 
Wallis test as appropriate. Significance is reported at * p < 0.05, ** p < 0.01, *** p <0.001, 495 
and NS = not significant. 496 
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Figure 1 – Nelfinavir markedly enhances ER stress in Tsc2-/- MEFs when combined with 595 
proteasome inhibitors. (A) Tsc2+/+ and Tsc2-/- MEFs were treated for 6 h with either DMSO 596 
vehicle, 20 µM nelfinavir (NFV), 1 µM MG132, 50 nM bortezomib (BTZ), alone or in 597 
combination where indicated. Cells were harvested and total protein levels of TSC2, IRE1α, 598 
ATF4, CHOP, GADD34 and β-actin were detected by western blot. Anti-ubiquitin antibodies 599 
were used to determine the relative level of poly-ubiquitinated protein (n=3). (B) Xbp1 600 
mRNA splicing was determined following treatments as indicated. PCR products were 601 
resolved on agarose gels (unspliced = 480 bp upper band, spliced = 454 bp lower band, n=3). 602 
The proportion of spliced Xbp1 (Xbp1s) is graphed below. (C) Chop and Bip mRNA levels 603 
were analysed following 6 h dual treatment and standardised against Actb mRNA (n=3). (D) 604 
Tsc2-/- MEFs were pre-treated with 2 μM GSK2606414 (PERK inhibitor) for 30 min, where 605 
indicated, before being treated with 20 µM nelfinavir and 50 nM bortezomib for 6 h. Protein 606 
expression for CHOP and β-actin was then determined by western blot analysis (n=3). (E) 607 
The proteasome activity of drug-treated samples, as indicated, was determined by 608 
monitoring the turnover of the fluorescent chymotrypsin-like substrate (n=3). Statistics 609 
given are relative to the Tsc2+/+ DMSO control. (F) Levels of protein synthesis were 610 
determined for control, single and dual treated cells as indicated (n=5). 611 
Figure 2 – Nelfinavir enhances the cytotoxicity of bortezomib in Tsc2-/- but not in Tsc2+/+ 612 
MEFs. (A) Tsc2+/+ and Tsc2-/- MEFs were treated with either DMSO vehicle, 1 µM MG132, 613 
50 nM bortezomib (BTZ), 20 µM nelfinavir (NFV) alone or in combination where indicated 614 
over 24 h. Cells were then subjected to flow cytometry following DRAQ7 staining. DRAQ7 615 
exclusion (below line) represents the viable cell population, whilst positive DRAQ7 staining 616 
(above line) indicates cell death. The number of DRAQ7-stained Tsc2+/+ and Tsc2-/- MEFs 617 
are graphed in (B) (n=3). (C) Tsc2+/+ and Tsc2-/- MEFs were treated for 24 h with either 618 
DMSO, 20 µM nelfinavir (NFV), 50 nM bortezomib (BTZ) as single agents or in combination, 619 
as indicated, and then subjected to DNA fragmentation assays (n=5). (D) Tsc2+/+ and Tsc2-/- 620 
MEFs were treated for 24 h with 20 µM NFV combined with 50 nM BTZ in the presence or 621 
absence of 20 μM Z-VAD-FMK and analysed for cell death by flow cytometry with DRAQ7 622 
staining. The number of DRAQ7-stained Tsc2+/+ and Tsc2-/- MEFs are graphed (n=3). 623 
Figure 3 – Nelfinavir enhances the cytotoxicity of bortezomib in human lung and colon 624 
cancer cell lines. (A) NCI-H460 lung cancer and HCT116 colon cancer cells were treated with 625 
either DMSO vehicle, 50 nM bortezomib (BTZ), 20 µM nelfinavir (NFV) alone, or NFV 626 
combined with BTZ over 24 h. Cells were then subjected to flow cytometry with DRAQ7 627 
staining. DRAQ7 exclusion (below line) represents the viable cell population, whilst positive 628 
DRAQ7 staining (above line) indicates cell death. The number of DRAQ7-stained cells are 629 
graphed in (B) (n=3). (C) With the addition of Etoposide (100 µM), cells were treated as in 630 
(A) and total protein levels of Caspase-8 (CASP8), Caspase-3 (CASP3), PARP, GADD34, CHOP 631 
and β-actin were measured by western blot analysis (n=3). 632 
20 
 
Figure 4 – Nelfinavir and bortezomib synergise to selectively kill Tsc2-/- MEFs. Dose 633 
response curves were performed in Tsc2+/+ and Tsc2-/- MEFs using flow cytometry as a 634 
readout of cell death for nelfinavir (A), bortezomib (B) and the combination (C, D) (n=3). 635 
Synergy was assessed by examining cell death across a range of bortezomib concentrations, 636 
with or without 20 μM nelfinavir and calculated using CompuSyn software (E, F). Graphs 637 
show mean +/- S.E.M. 638 
 639 
Figure 5 – Nelfinavir and bortezomib prevent tumor spheroid growth in Tsc2-/- MEFs. (A) 640 
Tsc2-/- MEFs were plated in soft agar and treated over 11 days with either 20 µM nelfinavir 641 
(NFV), 20 nM bortezomib (BTZ), as single agents or in combination. Images of the colonies 642 
were taken and the diameters measured using ImageJ. Scale bar is 20 µm (n=4, with >100 643 
spheroids measured per condition, per replicate). (B) Tsc2-/- MEF spheroids were treated 644 
with DMSO vehicle control, 10 μM nelfinavir combined with 10 nM bortezomib (NFV BTZ), 645 
or 25 nM rapamycin (RAP), for 96 h. DRAQ7 was added for the final 36 h to monitor cell 646 
death before images were taken and quantified (n≥3, average of 12 spheroids per condition 647 
per replicate). (C) Spheroid diameter was determined from phase contrast images of (B) 648 
after 96 h drug treatment and plotted against DRAQ7 staining intensity. (D) Spheroids were 649 
re-plated onto standard tissue culture plates and grown under drug-free conditions. Images 650 
were taken every 24 h and the area of outgrowth calculated using Image J. Scale bar is 200 651 
µm. Relative outgrowth areas are graphed in (E). Statistics compare the 72 h timepoint. 652 
Graphs in A, B and E shown mean +/- S.E.M. (F) Treated spheroids were stained using 653 
phalloidin (actin - green in merged images) and DRAQ7 (nuclei - white) and imaged using 654 
confocal microscopy. A representative slice (x63 oil lens) through the spheroid is shown with 655 
a scale bar of 30 µm, alongside the maximum projection (x20 lens) with a scale bar of 75 656 
µm. 657 
Figure 6 – Nelfinavir and bortezomib upregulate early response genes for ER stress and 658 
cell death in Tsc2-/- MEFs, whilst pro-survival genes are downregulated. Tsc2+/+ and Tsc2-659 
/- MEFs were treated with either DMSO vehicle or combined nelfinavir (20 µM) and 660 
bortezomib (50 nM) for 6 h before processing for RNA sequencing (n=3). (A) Heatmap of a 661 
panel of ER stress-linked genes, a selection of which are highlighted graphically in (B). (C) 662 
Paired heatmaps from dual treated cells showing early response genes linked to cell survival 663 
and death which are highlighted in a volcano plot (D). (E) Tsc2+/+ and Tsc2-/- MEFs were 664 
treated with either DMSO vehicle or combined nelfinavir (20 µM) and bortezomib (50 nM) 665 
for 6 h, 16 h, and 24 h before extracting protein for western blot and probing for ATF4, 666 
CHOP, or β-actin (n=3).  667 
Figure 7 – Nelfinavir and bortezomib significantly reduce tumor volume in ELT3-V3 mouse 668 
xenografts, likely mediated through increased CHOP activity. ELT3-V3 tumor xenografts 669 
(n=14 per group) were treated with either vehicle control, 5mg/ml nelfinavir (NFV), 670 
0.05mg/ml bortezomib (BTZ), or NFV and BTZ in combination by intraperitoneal injection. 671 
(A) Tumor volume was recorded over 35 days before remaining mice were euthanised. 672 
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Significant reduction of tumor volume was observed at day 35 when comparing 673 
combination to vehicle control. (B) Representative images of tumors stained with 674 
haematoxylin (to indicate cell nuclei, blue) and an antibody against CHOP (brown). The 675 
percentage of CHOP-positive cells per treatment is indicated. (C) Western blot for ATF4, 676 
PARP cleavage, or β-actin were carried out in triplicate per treatment. 677 
Figure S1 - Nelfinavir enhances the cytotoxicity of bortezomib in ELT3-V3 but not in ELT3-678 
T3 cells (A) ELT3-V3 and ELT3-T3 cells were treated with either DMSO vehicle, 1 µM MG132, 679 
50 nM bortezomib (BTZ), 20 µM nelfinavir (NFV) alone, or NFV combined with either MG132 680 
or BTZ over 24 h. Cells were then subjected to flow cytometry with DRAQ7 staining. DRAQ7 681 
exclusion (below line) represents the viable cell population, whilst positive DRAQ7 staining 682 
(above line) indicates cell death. The number of DRAQ7-stained ELT3-V3 and ELT3-T3 cells 683 
are graphed in (B) (n=3). (C) Cells were treated as in (A) and total protein levels of Caspase-8 684 
(CASP8), Caspase-3 (CASP3), PARP, and β-actin were measured by western blot analysis. 685 
Figure S2 – Nelfinavir and bortezomib prevent tumor spheroid growth in ELT3-V3 cells. (A) 686 
ELT3-V3 spheroids were treated with DMSO vehicle control, 10 μM nelfinavir (NFV) 687 
combined with 10 nM bortezomib (BTZ), or 25 nM rapamycin (RAP), for 96 h. DRAQ7 was 688 
added for the final 36 h to monitor cell death before images were taken and quantified. (B) 689 
Spheroid diameter was determined from phase contrast images of (A) after 96 h drug 690 
treatment and plotted against DRAQ7 staining intensity. (C) Spheroids were then re-plated 691 
onto standard tissue culture plates and grown under drug-free conditions. Images were 692 
taken every 24 h and the area of outgrowth calculated using Image J. 693 
Figure S3 – Tsc2-/- MEFs have an increased basal level of ER stress which is exacerbated by 694 
nelfinavir and bortezomib treatment. (A) RNA sequencing data from DMSO vehicle-treated 695 
Tsc2+/+ and -/- MEFs was compared for basal gene expression changes. Genes linked to the 696 
ER stress response are highlighted. (B) RNA sequencing data from DMSO vehicle-treated 697 
Tsc2-/- MEFs and those treated with nelfinavir and bortezomib was compared for gene 698 
expression changes. Genes linked to the ER stress response are highlighted (n=3). 699 
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